18. Revenues from Contracts and Significant Customers

Disaggregation of Total Revenue

Product revenue is comprised of Journey’s five marketed products: Targadox®, Luxamend®, Ceracade®, Exelderm® and Ximino®. Substantially all of the product revenue is recorded in the U.S. The Company’s related party revenue is from Checkpoint’s collaboration with TGTX. The table below summarizes the Company’s revenue for the three and six months ending June 30, 2020 and 2019:

​

​

Significant Customers

For the three months ended June 30, 2020, none of the Company’s Dermatology Products customers accounted for more than 10.0% of its total gross product revenue.

For the six months ended June 30, 2020, one of the Company’s Dermatology Products customers accounted for more than 10.0% of its total gross product revenue.

For the three and six months ended June 30, 2019, gross product revenue under the 3PL Title Model accounted for approximately  84.0% and 86.0%, respectively.

At June 30, 2020, one of the Company’s Dermatology Products customers accounted for more than  10.0% of its total accounts receivable balance at 12.4%.

At June 30, 2019, one of the Company’s Dermatology Products customers accounted for more than  10% of total accounts receivable at  77.0%.